They exposed a humanized mice model bearing MOLM-13Luc AML cells to 2.5 mg/kg AZA for three doses, and 24 h after the last dose mice were treated with CD123 CAR-T cells, resulting in a lower tumor burden and longer survival on the AZA-treated group. The gene discussed is IL3RA; the disease is acute myeloid leukemia.